APPH Stock Overview
Engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Apontis Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €10.50 |
| 52 Week High | €10.60 |
| 52 Week Low | €4.12 |
| Beta | 1.23 |
| 1 Month Change | 4.48% |
| 3 Month Change | 8.70% |
| 1 Year Change | 132.30% |
| 3 Year Change | -38.95% |
| 5 Year Change | n/a |
| Change since IPO | -44.00% |
Recent News & Updates
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce
Oct 17Recent updates
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Oct 17Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce
Oct 17Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?
Jun 18Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk
Apr 05We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Dec 02Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%
Jul 29Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors
Apr 08Shareholder Returns
| APPH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.9% | 0.7% | 2.6% |
| 1Y | 132.3% | -13.3% | 13.4% |
Return vs Industry: APPH exceeded the German Pharmaceuticals industry which returned -13.3% over the past year.
Return vs Market: APPH exceeded the German Market which returned 13.4% over the past year.
Price Volatility
| APPH volatility | |
|---|---|
| APPH Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: APPH has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: APPH's weekly volatility has decreased from 8% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 177 | Bruno Wohlschlegel | apontis-pharma.de |
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany.
Apontis Pharma AG Fundamentals Summary
| APPH fundamental statistics | |
|---|---|
| Market cap | €87.47m |
| Earnings (TTM) | -€7.08m |
| Revenue (TTM) | €40.63m |
2.2x
P/S Ratio-12.4x
P/E RatioIs APPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APPH income statement (TTM) | |
|---|---|
| Revenue | €40.63m |
| Cost of Revenue | €15.72m |
| Gross Profit | €24.91m |
| Other Expenses | €31.99m |
| Earnings | -€7.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 61.31% |
| Net Profit Margin | -17.42% |
| Debt/Equity Ratio | 0% |
How did APPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/18 04:05 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apontis Pharma AG is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Orquera | First Berlin Equity Research GmbH |
| Tim Wunderlich | Hauck Aufhäuser Investment Banking |
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |